First in human trial of a type i positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288

Journal of Psychopharmacology

Volumn 31, Issue 4, 2017, Pages 434-441

  Gee, Kelvin W ^a   Olincy, Ann ^b   Kanner, Richard ^c   Johnson, Lynn ^b   Hogenkamp, Derk ^a   Harris, Josette ^b   Tran, Minhtam ^a   Edmonds, Stephen A ^b   Sauer, William ^b   Yoshimura, Ryan ^a   Johnstone, Timothy ^a   Freedman, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Anvyl LLC   (United States)

Author keywords

allosteric modulators; cognition; drug evaluation; nicotinic; Receptors; schizophrenia

Indexed keywords

BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; N (4 CHLOROPHENYL)ALPHA [[(4 CHLOROPHENYL)AMINO]METHYLENE] 3 METHYL 5 ISOXAZOLEACETAMIDE,; PLACEBO; UNCLASSIFIED DRUG; ANILIDE; AVL3288; BIOLOGICAL MARKER; ISOXAZOLE DERIVATIVE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUDITORY EVOKED POTENTIAL; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; ELIMINATION RATE CONSTANT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ALLOSTERISM; CLINICAL TRIAL; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFECTS; METABOLISM; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; YOUNG ADULT;

ADULT; ALLOSTERIC REGULATION; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANILIDES; BIOMARKERS; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; NEUROCOGNITIVE DISORDERS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; YOUNG ADULT;

EID: 85018742795     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881117691590     Document Type: Article

References (27)

1. Bazett H, (1920) An analysis of the time-relations of electrocardiograms. Heart 7: 353-370.
2. Dempster EL, Toulopoulou T, McDonald C, et al. (2006) Episodic memory performance predicted by the 2bp deletion in exon 6 of the "alpha 7-like" nicotinic receptor subunit gene. Am J Psychiatry 163: 1832-1834.
3. FDA (2016) The Drug Development Process: Step 3. Clinical Research. Available at: www.fda.gov/ForPatients/Approvals/Drugs/ucm405622 (. accessed December 2016).
4. Freedman R, (2014) Alpha7-nicotinic receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 65: 245-261.
5. Freedman R, Olincy A, Buchanan RW, et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
6. Giniatullin R, Nistri A, Yakel JL, (2005) Desensitization of nicotinic ACh receptors: Shaping cholinergic signaling. Trends Neurosci 28: 371-378.
7. Gold JM, Queern C, Iannone VN, et al. (1999) Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: Sensitivity, reliability, and validity. Am J Psychiatry 156: 1944-1950.
8. Grolien JH, Kakerud M, Ween H, et al. (2007) Distinct profiles of α7-nAChR positive allosteric modulators revealed by structurally diverse chemotypes. Mol Pharmacol 72: 715-724.
9. Haig G, Bain E, Robieson W, et al. (2016) A randomized, double-blind trial to assess the efficacy and safety of ABT-126, A selective α7 nicotinic acetylcholine receptor agonist in the treatment of cognitive impairment in subjects with schizophrenia. Am J Psychiatry 173: 827-835.
10. Harris JG, Kongs S, Allensworth D, et al. (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29: 1378-1385.
11. Hu M, Gopalakrishnan M, Li J, (2009) Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: Lack of cytotoxicity in PC12 cells and rat primary cortical neurons. Br J Pharmacol 158: 1857-1864.
12. Hurst RS, Hajós M, Raggenbass M, et al. (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: In vitro and in vivo characterization. J Neurosci 25: 4396-4405.
13. Keefe RSE, Meltzer HA, Dgetluck N, et al. (2015) Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40: 3053-3060.
14. Kitagawa H, Takenouchi T, Azuma R, et al. (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
15. Lieberman JA, Dunbar G, Segreti AC, et al. (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38: 968-975.
16. Lijffijt M, Moeller G, Boutros NN, et al. (2009) The role of age, gender, education, and intelligence in P50, N100, and P200 auditory sensory gating. J Psychophysiol 23: 52-62.
17. Ng HJ, Whittemore ER, Tran MB, et al. (2007) Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A 104: 8059-8064.
18. Nikiforuk A, Kos T, Holuj M, et al. (2016) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology 101: 389-400.
19. Nikiforuk A, Kos T, Potasiewica A, et al. (2015) Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol 25: 1300-1313.
20. Olincy A, Braff DL, Adler LE, et al. (2010) Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: Results from the Consortium on Genetics of Schizophrenia. Schizophr Res 119: 175-182.
21. Olincy A, Harris JG, Johnson LL, et al. (2006) Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
22. Peng X, Katz M, Gerzanich V, et al. (1994) Human alpha 7 acetylcholine receptor: Cloning of the alpha 7 subunits from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in Xenopus oocytes. Mol Pharmacol 45: 546-554.
23. Quick MW, Lester RA, (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457-478.
24. Thomsen MS, El-Sayed M, Mikkelsen JD, (2011) Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One 11: e27014.
25. Van Vleet TR, Bombick DW, Coulombe RA, (2001) Inhibition of human cytochrome P450 2E1 by nicotine, cotinine, and aqueous cigarette tar extract in vitro. J Toxicol Sci 64: 185-191.
26. Winterer G, Gallinat J, Brinkmeyer J, et al. (2013) Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64: 197-204.
27. Zhang XY, Liu L, Liu S, et al. (2012) Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 169: 974-981.